GLP-1 Peptide Atlas, by Delfa

Active not recruitingPhase 3

A Study of IBI362 9 mg in Chinese Adults With Obesity

A Randomized, Double-blind, Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of IBI362 9 mg in Chinese Participants With Obesity (GLORY-2)

Lead sponsor

Innovent Biologics (Suzhou) Co. Ltd.

Asset

Mazdutide

Subcutaneous · GLP-1 / glucagon dual

Listed sites

Recruiting sites

—

Enrollment

462

actual

Study population

Obesity / overweight

Key I/E criteria

•BMI ≥30•HbA1c 7-10%

Primary endpoints

•Body weight, % change•≥5% weight-loss responders

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06164873

Org study IDCIBI362B302

Timeline

Milestones

Study first posted2023-12-11actual

Study start2023-12-27actual

Last update posted2024-08-27actual

Primary completion2025-06-27estimated

Study completion2025-09-19estimated

Assets

Investigational agents

Mazdutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Male or female, age 18 years or older at the time of signing informed consent

•Have a BMI ≥30 kg/m2

•Have a history of at least one self-reported unsuccessful dietary effort to lose body weight

For subjects with T2D at screening:

•Have a diagnosis of T2D according to the WHO classification above or equal to 3 months prior to the day of screening

•Treated with either diet and excercise alone or on stable treatment with up to 3 oral antidiabetic medications alone or in any combination (EXCEPT GLP-1R agonists or DPP-4 inhibitors) for at least 2 months prior to the day of screening

•HbA1c 7.0-10.0% (both inclusive) at screening

•Fasting blood glucose ≤11.1 mmol/L at screening

Exclusion criteria

• A self-reported change in body weight above 5% within 3 months before screening

For subjects without T2D at screening:

• HbA1c ≥6.5% as measured by local laboratory at screening

For subjects with T2D at screening:

•Have history of proliferative diabetic retinopathy, diabetic macular edema or non-proliferative diabetic retinopathy that required acute treatment

•Have had 2 or more episodes of ketoacidosis, hyperosmolar state or lactic acidosis within 6 months before screening;

Endpoints (10)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Cardiometabolic biomarkers

Weight & body composition

6 endpoints

Primary/protocol endpoint

Percent Change from Baseline in Body Weight

Time frame:Week 60

Body weight, % change

percent change from baseline, improvement

Primary/protocol endpoint

Proportion of Participants who Achieve ≥5% Body Weight Reduction

Time frame:Week 60

≥5% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Proportion of Participants who Achieve ≥10% Body Weight Reduction

Time frame:Week 60

≥10% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Proportion of Participants who Achieve ≥15% Body Weight Reduction

Time frame:Week 60

≥15% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Proportion of Participants who Achieve ≥20% Body Weight Reduction

Time frame:Week 60

≥20% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Change from Baseline in Waist Circumference

Time frame:Week 60

Waist circumference, change

change from baseline, improvement

Cardiometabolic biomarkers

4 endpoints

Secondary/protocol endpoint

Change from Baseline in Systolic Blood Pressure

Time frame:Week 60

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Percent Change from Baseline in Triglycerides

Time frame:Week 60

Triglycerides, change

percent change from baseline, improvement

LOINC 2571-8

Secondary/protocol endpoint

Percent Change from Baseline in non-high-density lipoprotein cholesteroal

Time frame:Week 60

Non-HDL cholesterol, change

percent change from baseline, improvement

Secondary/protocol endpoint

Percent Change from Baseline in low-density lipoprotein cholesterol

Time frame:Week 60

LDL-C, change

percent change from baseline, improvement

LOINC 13457-7

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Gao L, Jiang H, Cai H, Tian J, Shi B, Qiu W, Huang C, Han J, Zhang S, Pang S, Bi Y, Chen L, Gu X, Han J, Ma Q, Deng H, Wang Y, Li L, Han-Zhang H, Qian L, Ji L; GLORY-2 Trial Investigators. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA. 2026 Jun 7. doi: 10.1001/jama.2026.8142. Online ahead of print.
PMID42251595via clinicaltrials gov reference derived

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.